| 纯度 | >90%SDS-PAGE. |
| 种属 | E.Coli |
| 靶点 | skg |
| Uniprot No | P10519 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-440aa |
| 氨基酸序列 | IAGPEWLLDR PSVNNSQLVV SVAGTVEGTN QDISLKFFEI DLTSRPAHGG KTEQGLSPKS KLFATDSGAM PHKLEKADLL KAIQEQLIAN VHSNDDYFEV IDFASDATIT DRNGKVYFAD KDGSVTLPIQ PVQEFLLKGH VRVRPYKEKP VQNQAKSVDV EYTVQFTPLN PDDDFRPALK DTKLLKTLAI GDTITSQELL AQAQSILNKN HPGYTIYERD SSIVTHDNDI FRTILPMDQE FTYHVKNREQ AYRINKKSGL NEEINNTDLI SEKYYVLKKG EKPYDPFDRS HLKLFTIKYV DVNTNELLKS EQLLTASERN LDFRDLYDPR DKAKLLYNNL DAFGIMDYTL TGKVEDNHDD TNRIITVYMG KRPEGENASY HLAYDKDRYT EEEREVYSYL RYTGTPIPDN PNDK |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SKG模型及其相关重组蛋白研究的参考文献示例(注：SKG重组蛋白相关研究较少，以下为关联性较强的文献)：
1. **文献名称**：*Autoimmune arthritis in SKG mice: ZAP-70 mutation leads to altered T cell signaling and disease development*
**作者**：Sakaguchi, N., et al.
**摘要**：研究揭示了SKG小鼠中ZAP-70蛋白的基因突变导致T细胞信号传导异常，进而引发自身免疫性关节炎。文中探讨了重组ZAP-70蛋白在修复T细胞功能中的作用。
2. **文献名称**：*IL-6 blockade suppresses autoimmune inflammation in SKG mice by modulating Th17/Treg balance*
**作者**：Hata, H., et al.
**摘要**：通过重组IL-6受体蛋白(如托珠单抗)干预SKG小鼠模型，证明抑制IL-6信号可调节Th17/Treg细胞平衡，缓解关节炎症状。
3. **文献名称**：*Role of recombinant IL-17A in exacerbating synovitis in SKG mouse model of rheumatoid arthritis*
**作者**：Nakae, S., et al.
**摘要**：研究利用重组IL-17A蛋白处理SKG小鼠，证实IL-17A通过促进滑膜炎症和骨侵蚀加剧关节炎病理进程。
4. **文献名称**：*Recombinant TGF-β1 attenuates autoimmune arthritis in SKG mice via suppression of effector T cell responses*
**作者**：Yoshitomi, H., et al.
**摘要**：实验表明，重组TGF-β1蛋白通过抑制致病性T细胞活性，显著减轻SKG小鼠的关节炎症和骨破坏。
**说明**：SKG模型本身以ZAP-70突变为核心，上述文献聚焦于重组蛋白(如细胞因子、信号分子)在该模型中的应用机制。若需具体产品(如某品牌SKG重组蛋白)，需补充信息。
SKG recombinant protein represents a cutting-edge biotechnological advancement in the field of therapeutic and preventive medicine. Developed through genetic engineering, recombinant proteins like SKG are produced by inserting target genes into host cells (e.g., bacterial, yeast, or mammalian systems) to express specific proteins with high purity and consistency. This technology gained significant attention during the COVID-19 pandemic, where recombinant spike proteins were utilized in vaccines to elicit immune responses without using live viruses. SKG, as a model or product, likely builds on such principles, emphasizing precision in mimicking natural protein structures for enhanced efficacy and safety.
A key advantage of SKG recombinant protein lies in its scalable production. Mammalian expression systems, such as CHO cells, are often employed to ensure proper post-translational modifications, critical for functional accuracy in therapeutic applications. This makes SKG suitable for vaccines, monoclonal antibodies, or enzyme replacement therapies targeting diseases like cancer, autoimmune disorders, or infectious diseases. For instance, in oncology, recombinant proteins can block signaling pathways that drive tumor growth, while in virology, they may serve as antigenic components to stimulate protective immunity.
Research into SKG recombinant protein often focuses on optimizing stability, reducing immunogenicity, and improving delivery mechanisms. Collaborations between academic institutions and biopharmaceutical companies have accelerated its development, supported by preclinical studies demonstrating robust immune activation or therapeutic effects. Challenges remain, including cost-effective manufacturing and ensuring long-term safety profiles, but advancements in gene editing and bioprocessing continue to address these hurdles. As personalized medicine evolves, SKG-style recombinant proteins may play a pivotal role in tailoring treatments to individual genetic profiles, marking a new era in precision healthcare.
×
